

TO THE JOY OF OPTIONS

Exploring targeted treatment approaches in gMG

Saturday,
26 October 2024
13:00–14:00 AWST

Room M1, Level 2,
Perth Convention
and Exhibition
Centre

13:00–13:10

Targeting a new era for gMG management

Associate Professor Stephen Reddel



Dr Ali A. Habib

Clinical Professor, Neurology,
University of California, Irvine,
Orange, CA, USA

13:10–13:30

Understanding targeted therapies in gMG

Dr Ali A. Habib and Professor James F. Howard, Jr.



Professor James F. Howard, Jr.

Professor of Neurology,
Medicine & Allied Health, The
University of North Carolina at
Chapel Hill, Chapel Hill, NC, USA

13:30–13:45

Connecting research to clinical practice – hands on with targeted therapies

Associate Professor Stephen Reddel, Dr Ali A. Habib and
Professor James F. Howard, Jr.



Associate Professor Stephen Reddel

Staff Specialist Neurologist at Concord
Repatriation General Hospital Sydney,
and Consultant Neurologist at the Brain
& Mind Centre, The University of Sydney,
Sydney, Australia

13:45–13:55

Faculty Q&A

Associate Professor Stephen Reddel, Dr Ali A. Habib and
Professor James F. Howard, Jr.

13:55–14:00

Looking to the future of gMG management

Associate Professor Stephen Reddel



*"I'm heading straight
for the garden"*

gMG, generalised myasthenia gravis.

A UCB-sponsored satellite symposium at the 18th International Congress on Neuromuscular Diseases (ICNMD) 2024. This presentation was approved by the Scientific Program Committee as an independent activity held in conjunction with the 18th International Congress on Neuromuscular Diseases. This material is not sponsored or endorsed by ICNMD 2024. This symposium is initiated, funded and organised by UCB Biopharma SRL. UCB medicines will be discussed at this meeting. This symposium is intended for healthcare professionals only who are registered for the ICNMD congress. © UCB Biopharma SRL, 2024. All rights reserved. UCB Australia Pty Ltd (ABN 48 005 799 208). Level 1, 1155 Malvern Road, Malvern VIC 3144. Telephone (03) 9828 1800. Facsimile (03) 9828 1860. Date of preparation: October 2024 GL-RZ-2400044



Inspired by patients.
Driven by science.